Search results
Results from the WOW.Com Content Network
Pfizer posted strong earnings in the third quarter as investors worry about the stock's value. Pfizer raises full-year guidance by $1.5 billion amid activist investor pressure [Video] Skip to main ...
Pfizer CEO Albert Bourla is breathing a little easier after strong third quarter earnings results Tuesday and after the company raised full-year guidance by $1.5 billion, bringing an end to a ...
Pfizer’s stock hit an all-time high of $61.25 in December 2021 as its COVID shot, as well as its antiviral treatment Paxlovid, helped billions return to work, school, and public life.
PFE Revenue (TTM) data by YCharts Pfizer's vaccine (Comirnaty) and treatment option (Paxlovid) combined for $56 billion in revenue in 2022. Those two products represented just $2.4 billion of ...
One stock that just can't seem to catch a break of late is Pfizer (NYSE: PFE). Given how well Pfizer has performed in recent years due to its COVID-19 vaccine and pill (its revenue topped $100 ...
Although Pfizer seems headed toward big things over the coming years, the stock has immediate appeal. Here are three reasons to consider buying Pfizer like there's no tomorrow -- today. 1.
Pfizer beat on earnings in the first quarter of 2024, giving its stock a much-needed 7% boost Wednesday.The company reported $14.9 billion in revenue, down 19% compared to last year. That beat ...
Pfizer's trailing-12-month (TTM) revenue is $59.3 billion, whereas its TTM normalized diluted earnings per share (EPS) is $1.55. Pfizer Just Reassured Investors, but Is the Stock a Buy? Skip to ...